Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Thursday 1 January 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Patients

Physician with gloved hands holds a patient's hands with CHE

Prioritising dermatology to reduce pressure on healthcare se...

Chronic skin conditions, particularly CHE, remain some of the most underestimated, yet pervasive, challenges affecting people across Europe.

Oncology

pharmaphorum podcast Episode 238, Andrew Newland, ANGLE

Aligning with national efforts to modernise cancer diagnosti...

Andrew Newland, CEO of ANGLE, explains why live cell liquid biopsies should become standard in oncology.

Digital

NHS spelled out on wooden blocks beside stethoscope

How unified data can supercharge the NHS in 2026

With stronger foundations and a growing national appetite for change, 2026 could be the year when unified data becomes routine practice.

Digital

Digitally versed HCPs

Healthcare Predictions for the UK in 2026

Digital systems are steadily replacing legacy software and automation tools roll out at speed to cut back the time clinicians spend on manual tasks.

Patients

pharmaphorum podcast Episode 237, Vinay Patel

Rethinking prescription drug affordability, with Vinay Patel

Vinay Patel, an innovative pharmacist, discuss the intricacies of drug pricing and accessibility in the US.

Market Access

nine for 2023

Nine for 2023, part three: thriving or surviving?

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry

Digital

healthcare portal

How can pharma teams optimise their HCP portals to strengthe...

In recent years, pharma companies have invested heavily in their healthcare provider (HCP) portals, along with other digital solutions, to account for the reduction in face-to-face time bet

Patients

Pharma Integrates 2022 London

A glance back to Pharma Integrates, London 2022 – part iii

Run by Life Science Integrates, Pharma Integrates was in its 11th year in 2022.

Load more results

Sales & Marketing

Sales & Marketing

Wooden block pyramid leading to engagement target

From omnichannel to optichannel: Redefining personalised eng...

Optichannel presents new opportunities, layering in a deep understanding of customer behaviours and preferences to enhance performance.

Sales & Marketing

Patent spelled out in wooden blocks on top of legal documents

The hidden IP problem holding innovators back

For organisations active in the US market, the impact of patent marking is financial, not administrative.

Digital

Digital

NHS spelled out on wooden blocks beside stethoscope

How unified data can supercharge the NHS in 2026

With stronger foundations and a growing national appetite for change, 2026 could be the year when unified data becomes routine practice.

Digital

Digitally versed HCPs

Healthcare Predictions for the UK in 2026

Digital systems are steadily replacing legacy software and automation tools roll out at speed to cut back the time clinicians spend on manual tasks.

Market Access

Market Access

Group of ethnically diverse women

Women's health: Predictions for 2026

A forward glance at new funding vehicles, national strategies, and innovative solutions reshaping the underlying infrastructure of women's care.

Market Access

Images of pills on dominoes pieces, one being removed from the line

UK pharma policy at a turning point: NICE threshold reform, ...

The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.

Editor's Picks

US BIOSECURE Act passed by Congress

Lilly points to long-lasting weight loss with orforglipron

As year-end nears, pharma groups plump up their pipelines

CDC signs off on advice ending universal hepatitis B jabs

Enhertu moves into frontline breast cancer treatment

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

pharmaphorum podcast Episode 238, Andrew Newland, ANGLE

Aligning with national efforts to modernise cancer diagnosti...

Andrew Newland, CEO of ANGLE, explains why live cell liquid biopsies should become standard in oncology.

Oncology

Cancer cell on pink background

ESMO25: Perspective on ‘inside-out oncology’ and targeted al...

Perspective Therapeutics is advancing image‑guided, targeted alpha‑particle therapies (TATs). We spoke to Thijs Spoor at ESMO 2025 to find out more.

Oncology

pharmaphorum podcast Episode 229, Craig Eagle, Guardant Health

How blood tests can inform cancer treatment decisions, with ...

Craig Eagle, chief medical officer of Guardant Health, discusses blood as a rich source of biomarker development in cancer prognosis.

Patients

Patients

Physician with gloved hands holds a patient's hands with CHE

Prioritising dermatology to reduce pressure on healthcare se...

Chronic skin conditions, particularly CHE, remain some of the most underestimated, yet pervasive, challenges affecting people across Europe.

Patients

pharmaphorum podcast Episode 237, Vinay Patel

Rethinking prescription drug affordability, with Vinay Patel

Vinay Patel, an innovative pharmacist, discuss the intricacies of drug pricing and accessibility in the US.

Patients

diabetes management tools and medications

Simplifying care to close the gap: Rethinking treatment burd...

Simplifying the complexity of medical treatments extends beyond convenience to improving equity.

R&D

R&D

Green lab concept

How labs can lead the way in sustainability

Through focused strategies and industry collaboration, labs can significantly reduce waste, energy usage, and emissions.

R&D

GLP-1 under magnifying glass

Searching for new weight loss treatments

Using IP intelligence to guide R&D activity can also help companies to develop treatments that are more effective, with fewer side effects.

R&D

pharmaphorum podcast Episode 235, Markus Vossman, Illumina

On genomics, NGS, and doing much more good than bad, with Ma...

Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.

Editor's Picks

US BIOSECURE Act passed by Congress

Lilly points to long-lasting weight loss with orforglipron

As year-end nears, pharma groups plump up their pipelines

CDC signs off on advice ending universal hepatitis B jabs

Enhertu moves into frontline breast cancer treatment

News

Vanda ends 40-year hiatus for new motion sickness drugs

Vanda ends 40-year hiatus for new motion sickness drugs

The FDA has delivered some end-of-year cheer to Vanda Pharma after approving Nereus, its drug for the prevention of motion sickness.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company